Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Dec 2;87(12):1365-9.
doi: 10.1038/sj.bjc.6600660.

Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

D A Cameron  1 , A Anderson, E Toy, T R J Evans, J H Le Vay, I C S Kennedy, R J Grieve, T J Perren, A Jones, J Mansi, J Crown, R C F Leonard
Affiliations
Clinical Trial

Block sequential adriamycin CMF--optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?

D A Cameron et al. Br J Cancer. .

Abstract

After the publication of the 10-year survival data from Milan on the adjuvant use of the block sequential regimen consisting of four cycles of adriamycin followed by eight cycles of intravenous CMF, many centres adopted this as standard of care for high risk, multiple node-positive breast cancer. For this reason it was identified as the standard arm for the Anglo-Celtic adjuvant high-dose chemotherapy trial. This study reports on the experience of this regimen in 329 women with early breast cancer involving at least four axillary nodes, who were treated outside any adjuvant chemotherapy trial. At a median follow-up of 3 years, the overall 5-year disease-free survival is 61%, and the overall survival is 70%. These data confirm the efficacy of this regimen in non-trial patients, and, for the same high risk subgroup, indicate that this approach offers an outcome at least as good as that seen in the CALGB 9344 AC-Taxol arm, and the NCIC days 1 and 8 CEF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival for all patients with 4+ nodes.
Figure 2
Figure 2
Disease-free survival for all patients with 4+ nodes.
Figure 3
Figure 3
Overall survival by number of involved nodes.
Figure 4
Figure 4
Disease-free survival by number of involved nodes.
See this image and copyright information in PMC

References

    1. BerghJWiklundTEriksteinBLidbrinkELindmanHMalmstromPKellokumpu-LehtinenPBengtsson NOSoderlundGAnkerGWistEOttossonSSalminenELjungmanPHolteHNilssonJBlomqvistCWilkingN2000Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study Lancet 35613841391 - PubMed
    1. BonadonnaGZambettiMValagussaP1995Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results[see comments]JAMA 273542547 - PubMed
    1. BuzzoniRBonadonnaGValagussaPZambettiM1991Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes J Clin Oncol 921342140 - PubMed
    1. Early Breast Cancer Trialists Collaborative Group1998Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352930942 - PubMed
    1. Early Breast Cancer Trialists Collaborative Group2000. Unpublished Overview data for polychemotherapy for early breast cancer - PubMed

MeSH terms

Supplementary concepts